Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
10.1007/s11596-015-1492-4
- Author:
Di-min NIE
1
;
Qiu-ling WU
2
;
Xia-xia ZHU
2
;
Ran ZHANG
2
;
Peng ZHENG
2
;
Jun FANG
2
;
Yong YOU
2
;
Zhao-dong ZHONG
2
;
Ling-hui XIA
2
;
Mei HONG
3
Author Information
1. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. 695399570@qq.com.
2. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
3. Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. meihongcncn@aliyun.com.
- Publication Type:Journal Article
- Keywords:
acute graft-versus-host disease;
allogeneic hematopoietic stem cell transplantation;
angiogenic factors;
endothelial damage
- MeSH:
Acute Disease;
Adolescent;
Adult;
Angiogenesis Inducing Agents;
immunology;
metabolism;
pharmacology;
Angiopoietin-1;
genetics;
immunology;
pharmacology;
Angiopoietin-2;
genetics;
immunology;
pharmacology;
Antineoplastic Agents;
therapeutic use;
Female;
Gene Expression Regulation, Neoplastic;
Graft vs Host Disease;
genetics;
immunology;
pathology;
Hematopoietic Stem Cell Transplantation;
Human Umbilical Vein Endothelial Cells;
cytology;
drug effects;
immunology;
Humans;
Leukemia, Myeloid;
genetics;
immunology;
pathology;
therapy;
Lymphoma, Non-Hodgkin;
genetics;
immunology;
pathology;
therapy;
Male;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
genetics;
immunology;
pathology;
therapy;
Retrospective Studies;
Signal Transduction;
Transplantation, Homologous;
Tumor Necrosis Factor-alpha;
pharmacology;
Vascular Endothelial Growth Factor A;
genetics;
immunology
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2015;35(5):694-699
- CountryChina
- Language:English
-
Abstract:
Acute graft-versus-host disease (aGVHD) is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the mechanisms of aGVHD are not well understood. We aim to investigate the roles of the three angiogenic factors: angiopoietin-1 (Ang-1), Ang-2 and vascular endothelial growth factor (VEGF) in the development of aGVHD. Twenty-one patients who underwent allo-HSCT were included in our study. The dynamic changes of Ang-1, Ang-2 and VEGF were monitored in patients before and after allo-HSCT. In vitro, endothelial cells (ECs) were treated with TNF-β in the presence or absence of Ang-1, and then the Ang-2 level in the cell culture medium and the tubule formation by ECs were evaluated. After allo-HSCT, Ang-1, Ang-2 and VEGF all exhibited significant variation, suggesting these factors might be involved in the endothelial damage in transplantation. Patients with aGVHD had lower Ang-1 level at day 7 but higher Ang-2 level at day 21 than those without aGVHD, implying that Ang-1 may play a protective role in early phase yet Ang-2 is a promotion factor to aGVHD. In vitro, TNF-β promoted the release of Ang-2 by ECs and impaired tubule formation of ECs, which were both weakened by Ang-1, suggesting that Ang-1 may play a protective role in aGVHD by influencing the secretion of Ang-2, consistent with our in vivo tests. It is concluded that monitoring changes of these factors following allo-HSCT might help to identify patients at a high risk for aGVHD.
